Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform, which are designed to assess and treat severe emphysema/COPD patients [2] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, recognized as a standard of care treatment option for severe emphysema [2] Product and Market - The Zephyr Valve is designated as a "breakthrough device" by the FDA, highlighting its innovative nature and potential impact on patient care [2] - The Zephyr Valve is included in global treatment guidelines, indicating its widespread acceptance and adoption in the medical community [2] Investor Relations - Pulmonx Corporation will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2024, at 5:00 AM PT / 8:00 AM ET [4] - A live and archived webcast of the presentation will be available on the "Investors" section of the Pulmonx website [1]